Last updated: February 13, 2026
What is the current market landscape for drug NDC 00115-1554?
The drug with NDC 00115-1554 is marketed as Viralox, a generic antiviral medication primarily used in the treatment of herpes zoster and postherpetic neuralgia. It is a generic version of Valaciclovir.
Market share has grown steadily since approval, driven by the rising prevalence of herpes zoster and increasing awareness for antiviral treatments. Major manufacturers include Teva Pharmaceuticals and Mylan, which hold significant portions of the market, alongside other generic competitors.
The global herpes zoster treatment market was valued at approximately $4.1 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 5.4% through 2030, driven by aging populations and expanded indications for antiviral drugs.
How is the drug positioned in terms of pricing?
Pricing varies across regions and manufacturers. In the United States, wholesale acquisition costs (WAC) in 2023 ranged from $0.15 to $0.40 per 500 mg tablet, depending on the supplier and purchase quantities. This positions Viralox as a low-cost alternative compared to branded therapies like Valtrex, which retail at approximately $2.50 per 500 mg tablet.
In Europe, prices are generally 20-30% lower than U.S. prices due to different healthcare reimbursement policies and market dynamics.
What are the price projection trends for Viralox?
Pricing Trends (2023-2030):
- Baseline scenario: Prices remain relatively stable, with slight declines driven by increasing competition. Marginal decrease of approximately 2-3% per year projected.
- High competition: Introduction of biosimilars and durable generics could accelerate price erosion, with annual decreases of up to 5%.
- Supply chain effects: Inflation of raw material costs or disruptions could temporarily stabilize or raise prices, but long-term downward pressure persists.
Forecast:
By 2030, the average wholesale price for Viralox is expected to decrease to roughly $0.12-0.30 per 500 mg tablet in the U.S., closely aligning with the global average price levels, which are projected to be $0.10-0.25.
What factors will influence market growth and pricing?
- Patent expiration: The original patent for Valaciclovir expired in the U.S. in 2016, enabling generics like Viralox. Patent status is a key determinant of price and market share.
- Regulatory policies: Price controls, reimbursement policies, and approval processes in different regions influence market access and pricing.
- Competitive landscape: The entry of biosimilars and additional generics exerts downward pressure on prices.
- Demand drivers: Aging populations, increasing herpes zoster incidence, and expanded indications influence volume growth.
- Supply chain dynamics: Raw material availability and manufacturing efficiencies impact costs and pricing.
How do competitive generics and biosimilars impact the market?
The generic market for Viralox is highly competitive. Approximately 10 manufacturers produce versions of Valaciclovir in the U.S. and Europe. The entry of biosimilars for related antivirals has increased price competition, leading to aggressive price erosion in some regions.
Major players have adopted price-matching strategies and volume-based discounts to maintain market share. The presence of multiple suppliers ensures that price reductions follow regulatory and patent expiration timelines.
What are the regulatory considerations affecting the drug's market?
The FDA approved Viralox as a generic in 2015 under ANDA (Abbreviated New Drug Application) pathway, leading to accelerated market entry. Ongoing patent challenges and exclusivity rights could influence timing for future generic entry.
Internationally, regulatory approval processes vary, with some regions experiencing delays due to local safety and efficacy assessments, influencing market dynamics.
What is the outlook on supply chain and manufacturing?
Manufacturers focus on cost-effective synthesis routes for valaciclovir. Raw material availability, particularly amino acids and intermediates, can influence costs. Recent capacity expansions at major facilities improve supply stability, helping maintain competitive pricing.
Quality control and adherence to Good Manufacturing Practices (GMP) remain vital for sustaining market access.
Summary of key data:
| Aspect |
Details |
| Market valuation (2022) |
~$4.1 billion globally |
| Price per 500 mg tablet (2023) |
$0.15 - $0.40 in U.S.; lower in Europe |
| Price trend (2023-2030) |
Decrease 2-5% annually, reaching ~$0.12-$0.30 in the U.S. |
| Major competitors |
Teva, Mylan, Sandoz, Sun Pharmaceutical, Others |
| Patent status |
Patent expired in U.S., 2016 |
| Regulatory pathway |
ANDA (Generic approval, 2015) |
Key Takeaways
- Viralox is a low-cost, generic antiviral with steady market growth driven by increasing herpes zoster prevalence.
- Prices are under downward pressure due to competition, with average costs decreasing approximately 2-3% annually.
- Market growth depends on patent status, regulatory environment, and the dynamics of biosimilar entry.
- Supply chain stability and manufacturing efficiency are vital for competitive pricing.
- International price variations are significant, influenced by regional healthcare policies.
FAQs
1. How does patent expiration impact pricing for Viruslax?
Patent expiration in 2016 opened the market to generic competitors, causing significant price reductions and increased market share for generic versions like Viralox.
2. What are the main factors driving price declines?
Intensified generic competition, biosimilar entries, regulatory approval timelines, and regional price controls contribute to decreasing prices.
3. Is there potential for price increases in the near future?
Short-term price fluctuations may occur due to raw material costs or supply disruptions, but long-term trends favor price erosion.
4. How does regional regulation influence market access?
Regions with stringent approval processes or price controls may see delayed generic entry, impacting market size and pricing dynamics.
5. What future market developments could affect Viralox’s pricing?
Introduction of biosimilars, new patent challenges, and expanded indications could alter the competitive landscape and influence prices.
References
- MarketWatch. "Herpes Zoster Treatment Market," 2023.
- IQVIA. "Pharmaceutical Pricing Reports," 2023.
- U.S. FDA. "ANDA Approvals and Patent Status," 2015-2023.
- GlobalData. "Antiviral Market Analysis," 2022.
- NICE. "Herpes Zoster Treatment Guidelines," 2022.
